A U.S. Food and Drug Administration (FDA) advisory panel has voted to ease restrictions on several controversial peptide drugs promoted online for anti-aging, muscle growth and healing despite limited evidence of their safety or effectiveness in humans, marking a key regulatory step toward allowing them to be prescribed through specialized pharmacies.
America’s Peptide Boom Just Cleared a Major Regulatory Hurdle
The panel narrowly recommended allowing compounding pharmacies to produce peptides including BPC-157, TB-500 and KPV. While the FDA is not required to adopt the recommendation, it often follows the advice of its advisory committees.
The vote aligns with Health Secretary Robert F. Kennedy Jr.’s efforts to loosen restrictions on peptides after the Biden administration tightened oversight of the industry. Kennedy has previously described himself as a “big fan” of the compounds and pledged to ease limits on their use.
Peptides are short chains of amino acids that occur naturally in the body and are used in approved medicines for conditions such as diabetes. In recent years, however, injectable peptides marketed for unproven uses have gained popularity through social media, particularly after the rise of GLP-1 weight-loss drugs. Influencers have promoted combinations, or “stacks,” claiming they improve recovery, skin health, muscle growth and slow aging, despite limited clinical evidence.
Health experts have warned against their use, citing a lack of human clinical trials and uncertainty over long-term safety. Dr. Gevork Tatarian, a board-certified Florida cosmetic surgeon and co-owner of Elevé Cosmetic Surgery, says the FDA review could force physicians to adopt stricter standards around prescribing the compounds.
“This review raises the bar on how peptides are sourced, prescribed, and monitored. It pushes practices to prioritize well-studied, compliant therapies instead of relying on grey-market or ‘experimental’ blends,” Tatarian told Impact Newswire.
BPC-157, derived from a stomach protein, is marketed online as a treatment for gut health, tissue repair and inflammation and has been studied in animals for muscle healing. The U.S. Anti-Doping Agency says that because the compound has not been extensively studied in humans, “no-one knows if there is a safe dose, or if there is any way to use this compound safely to treat specific medical conditions.” The World Anti-Doping Agency prohibits its use in sport.
KPV is similarly promoted online for gut health, tissue repair, including acne treatment, and immune regulation, although it is not approved for human use.
Both compounds occupy a regulatory gray area. They can be bought online but have not been approved by the FDA for human use and are therefore not subject to the manufacturing standards required for approved pharmaceuticals.
Tatarian said consumers often mistakenly assume peptides are inherently safe because some occur naturally in the body. “Some peptides act more like powerful biologic drugs and can influence hormones, immune function, and metabolism,” he said.
He also warned patients against purchasing peptides from unregulated suppliers. “If a complication occurs, the patient may have little legal protection, and clinicians can be put in a difficult position if they are perceived to have endorsed or tolerated these sources,” he said.
Panel member Elizabeth Rebello, a pharmacist and anesthesiologist, said she voted against recommending BPC-157 “because of the lack of efficacy data” and “safety concerns.” Members who supported the recommendation cited “the greater good” and “medical freedom.”
The panel, which includes several members affiliated with clinics and businesses that sell peptides, is expected to continue deliberations on Friday. BPC-157 and KPV are among seven peptides under review for removal of restrictions that currently prevent compounding pharmacies from producing them after the FDA concluded during the Biden administration that they did not meet safety requirements.
Leave a Reply